New 2013 incidence peak in childhood narcolepsy: more than vaccination?
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
32909046
DOI
10.1093/sleep/zsaa172
PII: 5903541
Knihovny.cz E-resources
- Keywords
- H1N1 influenza, childhood narcolepsy, narcolepsy,
- MeSH
- Influenza, Human * epidemiology prevention & control MeSH
- Child MeSH
- Adult MeSH
- Incidence MeSH
- Humans MeSH
- Adolescent MeSH
- Narcolepsy * epidemiology etiology MeSH
- Vaccination MeSH
- Influenza Vaccines * MeSH
- Influenza A Virus, H1N1 Subtype * MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Asia MeSH
- Europe MeSH
- Names of Substances
- Influenza Vaccines * MeSH
Increased incidence rates of narcolepsy type-1 (NT1) have been reported worldwide after the 2009-2010 H1N1 influenza pandemic (pH1N1). While some European countries found an association between the NT1 incidence increase and the H1N1 vaccination Pandemrix, reports from Asian countries suggested the H1N1 virus itself to be linked to the increased NT1 incidence. Using robust data-driven modeling approaches, that is, locally estimated scatterplot smoothing methods, we analyzed the number of de novo NT1 cases (n = 508) in the last two decades using the European Narcolepsy Network database. We confirmed the peak of NT1 incidence in 2010, that is, 2.54-fold (95% confidence interval [CI]: [2.11, 3.19]) increase in NT1 onset following 2009-2010 pH1N1. This peak in 2010 was found in both childhood NT1 (2.75-fold increase, 95% CI: [1.95, 4.69]) and adulthood NT1 (2.43-fold increase, 95% CI: [2.05, 2.97]). In addition, we identified a new peak in 2013 that is age-specific for children/adolescents (i.e. 2.09-fold increase, 95% CI: [1.52, 3.32]). Most of these children/adolescents were HLA DQB1*06:02 positive and showed a subacute disease onset consistent with an immune-mediated type of narcolepsy. The new 2013 incidence peak is likely not related to Pandemrix as it was not used after 2010. Our results suggest that the increased NT1 incidence after 2009-2010 pH1N1 is not unique and our study provides an opportunity to develop new hypotheses, for example, considering other (influenza) viruses or epidemiological events to further investigate the pathophysiology of immune-mediated narcolepsy.
AP HP Pediatric Sleep Center CHU Robert Debré Paris France
Center for Investigation and Research in Sleep Lausanne University Hospital Lausanne Switzerland
Department of Anatomy and Neurosciences Amsterdam UMC Amsterdam The Netherlands
Department of Clinical Neurophysiology Institute of Psychiatry and Neurology Warsaw Poland
Department of Neurology Inselspital Bern University Hospital and University of Bern Bern Switzerland
Department of Neurology Sechenov University Moscow Russian Federation
Department of Sleep Medicine and Neuromuscular Disorders University of Münster Münster Germany
Eindhoven University of Technology Eindhoven The Netherlands
Helsinki Sleep Clinic Vitalmed Research Center Helsinki Finland
Institute of Molecular Medicine Portugal Medical Faculty Lisbon University Lisbon Portugal
IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy
Neurology Department Hephata Klinik Schwalmstadt Germany
Neurology Department Sleep Disorders Clinic Medical University of Innsbruck Innsbruck Austria
Neurology Department University Hospital Zurich Zurich Switzerland
Sleep and Epilepsy Center Neurocenter of Southern Switzerland Lugano Switzerland
Sleep Medicine Center Kempenhaeghe Heeze The Netherlands
Unidad de Neurofisiología y Trastornos del Sueño Hospital Vithas Internacional Madrid Madrid Spain
References provided by Crossref.org
Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering